This invention is related to systems for applying energy to lung airways and in particular, to a system and method for controlling the energy delivered to the airways using a PID algorithm to minimize error between a preset temperature and a measured temperature.
Various obstructive airway diseases have some reversible component. Examples include COPD and asthma. There are an estimated 10 million Americans afflicted with Asthma. Asthma is a disease in which bronchoconstriction, excessive mucus production, and inflammation and swelling of airways occur, causing widespread but variable airflow obstruction thereby making it difficult for the asthma sufferer to breathe. Asthma is a chronic disorder, primarily characterized by persistent airway inflammation. Asthma is further characterized by acute episodes of additional airway narrowing via contraction of hyper-responsive airway smooth muscle.
Reversible aspects of obstructive pulmonary disease generally include excessive mucus production in the bronchial tree. Usually, there is a general increase in bulk (hypertrophy) of the large bronchi and chronic inflammatory changes in the small airways. Excessive amounts of mucus are found in the airways and semisolid plugs of mucus may occlude some small bronchi. Also, the small airways are narrowed and show inflammatory changes. Reversible aspects include partial airway occlusion by excess secretions and airway narrowing secondary to smooth muscle contraction, bronchial wall edema and inflammation of the airways.
In asthma, chronic inflammatory processes in the airway play a central role in increasing the resistance to airflow within the lungs. Many cells and cellular elements are involved in the inflammatory process, particularly mast cells, eosinophils T lymphocytes, neutrophils, epithelial cells, and even airway smooth muscle itself. The reactions of these cells result in an associated increase in the existing sensitivity and hyper-responsiveness of the airway smooth muscle cells that line the airways to the particular stimuli involved.
The chronic nature of asthma can also lead to remodeling of the airway wall (i.e., structural changes such as thickening or edema) which can further affect the function of the airway wall and influence airway hyper-responsiveness. Other physiologic changes associated with asthma include excess mucus production, and if the asthma is severe, mucus plugging, as well as ongoing epithelial denudation and repair. Epithelial denudation exposes the underlying tissue to substances that would not normally come in contact with them, further reinforcing the cycle of cellular damage and inflammatory response.
In susceptible individuals, asthma symptoms include recurrent episodes of shortness of breath (dyspnea), wheezing, chest tightness, and cough. Currently, asthma is managed by a combination of stimulus avoidance and pharmacology.
Stimulus avoidance is accomplished via systematic identification and minimization of contact with each type of stimuli. It may, however, be impractical and not always helpful to avoid all potential stimuli.
Pharmacological management of asthma includes: (1) long term control through use of anti-inflammatories and long-acting bronchodilators and (2) short term management of acute exacerbations through use of short-acting bronchodilators. Both of these approaches require repeated and regular use of the prescribed drugs. High doses of corticosteroid anti-inflammatory drugs can have serious side effects that require careful management. In addition, some patients are resistant to steroid treatment. The difficulty involved in patient compliance with pharmacologic management and the difficulty of avoiding stimulus that triggers asthma are common barriers to successful asthma management. Current management techniques are thus neither completely successful nor free from side effects. Accordingly, it would be desirable to provide a system and method which improves airflow without the need for patient compliance.
Various energy delivering systems have been developed to intraluminally treat anatomical structures and lumen other than the lung airways. Unfortunately, the systems which are useful in treating such structures are generally not helpful in developing techniques to treat the lung airways because the lung airways are markedly different than other tissue structures. For example, lung airways are particularly heterogeneous. Variations in lung tissue structure occur for a number of reasons such as: the branching pattern of the tracheobronchial tree leads to local variation in the size and presence of airways; the vasculature of the lungs is a similar distributed network causing variation in size and presence of blood vessels; within the airways are variable amounts of differing structures such as cartilage, airway smooth muscle, and mucus glands and ducts; and energy delivery may also be influenced differently at the periphery, near the outer surface of a lung lobe, than in the central portion.
Lung airways also include a number of protruding folds. Other tissue structures such as blood vessels typically do not have the folds found in airways. Airways contain mucous and air whereas other structures contain different substances. The tissue chemistry between various lumens and airways is also different. In view of these differences, it is not surprising that conventional energy delivering systems cannot be universally applied to treat all tissue structures. Moreover, power shut-offs and other safety mechanisms must be precisely tailored to specific tissue so that the tissue is not harmed by application of excess energy.
Accordingly, an intraluminal RF energy delivering system that is capable of safely delivering RF energy to lung airways is desired. In particular, a system which is capable of controlling the temperature when treating an airway of an asthma or COPD patient is desired. It is also desirable to provide a system having built-in safeguards that shut the power off thereby preventing damage to the subject tissue or collateral tissue.
The present invention includes a system for delivering energy to an airway wall of a lung comprising an energy delivering apparatus and a PID controller. The energy delivering apparatus may include a flexible elongated member and a distal expandable basket having at least one electrode for transferring energy to the airway wall and at least one temperature sensor for measuring temperature (TM) of the airway wall when energy is delivered to the airway wall. The system further comprises a PID controller for determining a new power set point (Pi+1) based on an error (e) between a preset temperature (TS) and the measured temperature wherein the PID controller applies an algorithm having a variable gain factor (G).
In one variation of the present invention, the algorithm is Pi+1=Pi+G(αei+βei−1+γei−2) where α, β and γ are preset values. For instance, in one variation of the present invention, α is from 1 to 2; β is from −1 to −2; and γ is from −0.5 to 0.5. In another variation of the present invention, α, β, γ are 1.6, −1.6, and 0.0 respectively.
In another variation of the present invention, the gain factor used in the PID algorithm is reset 0.1 to 2 seconds after energy delivery has begun. The gain factor can also be reset 0.5 seconds after energy delivery has begun. The invention includes resetting G to 0.9 to 1.0 if a temperature rise in ° C. per Joule is less than or equal to 2.5; 0.4 to 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.2 to 0.3 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.1 to 0.2 if a temperature rise in ° C. per Joule is greater than 7.5. Initially, the gain factor is equal to 0.4 to 0.5 and preferably 0.45 to 0.47.
In another variation of the present invention, the PID algorithm is Pi+1=Pi+(G1ei+G2ei−1+G3ei−2) and G1, G2 and G3 are variable gain factors. The invention includes configuring the controller such that G1, G2 and G3 are reset to 0.9 to 2.00, −0.9 to −2.00 and 0.5 to −0.5 respectively if a temperature rise in ° C. per Joule is less than or equal to 2.5; to 0.40 to 1.00, −0.40 to −1.00 and 0.25 to −0.25 respectively if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.20 to 0.60, −0.20 to −0.60 and 0.15 to −0.15 respectively if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.10 to 0.40, −0.10 to −0.40 and 0.10 to −0.10 respectively if a temperature rise in ° C. per Joule is greater than 7.5. Each of the variable gain factors may be equal to a product of at least one preset value and at least one variable value.
In another variation of the present invention, the controller is configured such that the energy delivery is terminated if the energy delivered exceeds a maximum energy such as 120 joules.
In another variation of the present invention, the controller is configured to deliver energy for an activation time period such as up to 15 seconds, 8 to 12 seconds, or 10 seconds.
In another variation of the present invention, the controller is configured such that Ts is set at a value between 60 to 80° C., or 65° C.
In another variation of the present invention, the controller is configured to measure impedance and said energy delivery is terminated when said impedance drops below a preset impedance value such as 40 to 60 ohms.
In another variation of the present invention, the controller is configured to terminate the energy delivery if TM exceeds TS by a pre-selected value such as 10, 15 or 20° C.
In another variation of the present invention, the controller is configured to terminate the energy delivery if the output power is greater or equal to a nominal output power and TM drops by a critical temperature difference within a sampling period. The invention includes a nominal output power set at a value of at least 17 watts; the sampling period is set at a value of at least 0.5 seconds; and the critical temperature difference is 2° C.
In another variation of the present invention, the controller is configured to terminate the energy delivery if said TM averaged over a time window exceeds TS by a fixed temperature difference. The fixed temperature difference may be a value between 1 and 10° C. or 5° C. The time window is between 1 and 5 seconds or 2 seconds.
In another variation of the present invention, the controller is configured to terminate if the measured temperature drops by 10 or more ° C. in a sample period such as 1.0 seconds or 0.2 seconds.
Another variation of the present invention is a method for treating a lung by transferring energy from an active region of an energy delivery apparatus to an airway wall of the lung. The energy delivery apparatus includes a flexible elongate body and a distal section and the active region is located in the distal section. The energy delivery apparatus further has a temperature sensor located in the distal section for measuring a temperature (TM) of said airway wall and the method comprises the following steps: setting a preset temperature (TS); determining a power set point (Pi) to deliver energy from the active region to the target medium; measuring the TM using the temperature sensor, and determining a new power set point (Pi+1) based on an error (e) between the preset temperature (TS) and the measured temperature (TM) using a PID algorithm.
In yet another variation of the present invention, a process for transferring energy to a target medium using an energy delivery apparatus is provided. The energy delivery apparatus includes a flexible elongate body and a distal section wherein the distal section includes an expandable basket with at least one active region for transferring energy to the target medium. The energy delivery apparatus further has a temperature sensor located in the distal section for measuring a temperature (TM) of the target medium. The process comprises the following steps: setting a preset temperature (TS); determining a power set point (Pi) to deliver energy from the active region to the target medium; measuring TM using the temperature sensor; and determining a new power set point (Pi+1) based on an error (e) between the preset temperature (TS) and the measured temperature (TM) using an algorithm having a variable gain factor. The energy may be delivered to an airway wall of a lung in vivo, in vitro or to another target such as a sponge or towel which may be moistened with saline solution. Saline solution increases the conductivity of the target.
In one variation of the present invention, the algorithm is Pi+1=Pi+G(αei+βei−1+γei−2) where α, β and γ are preset values: α is from 1 to 2; β is from −1 to −2; and γ is from −0.5 to 0.5. In another variation of the present invention, α, β, γ are 1.6, −1.6, and 0.0 respectively.
In another variation of the present invention, the gain factor is reset 0.1 to 2 seconds after energy delivery has begun. The gain factor can also be reset 0.5 seconds after energy delivery has begun. The invention includes resetting G to 0.9 to 1.0 if a temperature rise in ° C. per Joule is less than or equal to 2.5; 0.4 to 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; to 0.2 to 0.3 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.1 to 0.2 if a temperature rise in ° C. per Joule is greater than 7.5. Initially, the gain factor is equal to 0.4 to 0.5 and preferably 0.45 to 0.47.
In another variation of the present invention, the energy delivery is terminated if the energy delivered exceeds a maximum energy such as 120 joules.
In another variation of the present invention, energy is delivered for an activation time period such as 0 to 15 seconds, 8 to 12 seconds, or 10 seconds.
In another variation of the present invention, TS is set at a value between 60 to 80, or 65° C.
In another variation of the present invention, impedance is measured and energy delivery is terminated when the impedance drops below a preset impedance value such as 40 to 60 ohms.
In another variation of the present invention, the energy is terminated if TM exceeds TS by a pre-selected value such as 10, 15 or 20° C.
In another variation of the present invention, energy is terminated if the output power is greater or equal to a nominal output power and TM drops by a critical temperature difference within a sampling period. In variations of the present invention, the nominal output power is set at a value of at least 17 watts; the sampling period is set at a value of at least 0.5 seconds; and the critical temperature difference is 2° C.
In another variation, the energy delivery apparatus is configured to deliver an amount of power up to a maximum power. The maximum power can be from 10 to 40 watts and preferably from 15 to 20 watts.
In another variation of the present invention, energy delivery is terminated if TM averaged over a time window exceeds TS by a fixed temperature difference. The fixed temperature difference may be a value between 1 and 10° C. or 5° C. The time window is between 1 and 5 seconds or 2 seconds.
In another variation of the present invention, the energy delivery is terminated if the measured temperature drops by 10 or more ° C. in a sample period such as 1.0 seconds or 0.2 seconds.
The invention will now be described in greater detail with reference to the various embodiments illustrated in the accompanying drawings:
The present invention includes a controller and an energy deliver apparatus to deliver energy to the airway walls of the lungs. Amongst other features, the controller includes a feedback loop having a variable gain factor as diagramed in
The present invention is particularly useful in treating lung tissue. This is surprising in view of the unique and complicated structure of lung tissue. Referring first to
Energy Delivering Device
As indicated above, the present invention includes a controller 32 and a device 30 through which it delivers energy to the target medium 34. A device 30 of the present invention should be of a size to access the bronchus or bronchioles of the human lung. The device may be sized to fit within bronchoscopes, preferably, with bronchoscopes having a working channel of 2 mm or less. The device may also include a steering member configured to guide the device to a desired target location. For example, this steering member may deflect a distal tip of the device in a desired direction to navigate to a desired bronchi or bronchiole.
The energy delivering apparatus 30 typically includes an elongate body having a proximal section and a distal section. The distal section features a radially expandable basket having a plurality of legs. The legs may be electrodes or have an active region defined by an insulated covering which contacts the medium to be treated. The basket is expanded with an actuator mechanism which may be provided in a handle attached to proximal end of the elongate body. Examples of energy delivering devices in accordance with the present invention are described in co-pending U.S. application Ser. No. 09/436,455 filed Nov. 8, 1999 which is hereby incorporated by reference in its entirety.
Temperature Sensor
The invention also includes a temperature detecting element. Examples of temperature detecting elements include thermocouples, infrared sensors, thermistors, resistance temperature detectors (RTDs), or any other apparatus capable of detecting temperatures or changes in temperature. The temperature detecting element is preferably placed in proximity to the expandable member.
The leads 139 may be placed at other locations along the leg 106 including an edge 405. Joining the leads 139 to the edge 405, however, is undesirable because of its relatively small bonding surface.
Preferably, insulating layers 430 and 440 are disposed between the thin film leads 139 and the basket leg 106. The insulating layers 430 and 440 electrically separate the leads 139 as well as electrically separate the leads from the leg 106. The insulating layers 430 and 440 limit the thermocouple junction to bond joints 450 and 460, which are optimally positioned on active region 420 of basket leg 106.
Controller
The present invention includes a controller which controls the energy to be delivered to the airways via an energy transfer device. The controller includes at least one of the novel features disclosed hereinafter and may also incorporate features in known RF energy controllers. An example of a RF generator which may be modified in accordance with the present invention is the FORCE™ 2 Generator manufactured by Valleylab, Boulder, Colo., U.S.A. Another suitable technique to generate and control RF energy is to modulate RF output of a RF power amplifier by feeding it a suitable control signal.
The controller and power supply is configured to deliver enough energy to produce a desired effect in the lung. The power supply should also be configured to deliver the energy for a sufficient duration such that the effect persists. This is accomplished by a time setting which may be entered into the power supply memory by a user.
The power supply or generator of the present invention can also employ a number of algorithms to adjust energy delivery, to compensate for device failures (such as thermocouple detachment), to compensate for improper use (such as poor contact of the electrodes), and to compensate for tissue inhomogeneities which can affect energy delivery such as, for example, subsurface vessels, adjacent airways, or variations in connective tissue.
The power supply can also include circuitry for monitoring parameters of energy. transfer: (for example, voltage, current, power, impedance, as well as temperature from the temperature sensing element), and use this information to control the amount of energy delivered. In the case of delivering RF energy, typical frequencies of the RF energy or RF power waveform are from 300 to 1750 kHz with 300 to 500 kHz or 450 to 475 being preferred. The RF power-level generally ranges from about 0-30 W but depends upon a number of factors such as, size of the electrodes. The controller may also be configured to independently and selectively apply energy to one or more of the basket leg electrodes.
A power supply may also include control modes for delivering energy safely and effectively. Energy may be delivered in open loop (power held constint) mode for a specific time duration. Energy may also be delivered in temperature control mode, with output power varied to maintain a certain temperature for a specific time duration. In the case of RF energy delivery via RF electrodes, the power supply may also operate in impedance control mode.
Temperature Control Mode
In a temperature control mode, the power supply may operate up to a 75° C. setting. That is, the temperature measured by the thermocouple can reach up to 75° C. before the power supply is shut off. The duration must be long enough to produce the desired effect, but as short as possible to allow treatment of all of the desired target airways within a lung. For example, up to 15 seconds is suitable, and more preferably 8 to 12 seconds with about 10 seconds per activation (while the device is stationary) being preferred. Shorter duration with higher temperature will also produce an acceptable acute effect.
It should be noted that different device constructions utilize different parameter settings to achieve the desired effect. For example, while direct RF electrodes typically utilize temperatures up to 75° C. in temperature control mode, resistively heated electrodes may utilize temperatures up to 90° C.
Energy Pulses and Energy Modulation
Short bursts or pulses of RF energy may also be delivered to the target tissue. Short pulses of RF energy heat the proximal tissue while the deeper tissue, which is primarily heated by conduction through the proximal tissue, cools between the bursts of energy. Short pulses of energy therefore tend to isolate treatment to the proximal tissue.
The application of short pulses of RF energy may be accomplished by modulating the RF power waveform with a modulation waveform. Modulating the RF power waveform may be performed while employing any of the other control algorithms discussed herein so long as they are not exclusive of one another. For example, the RF energy may be modulated while in a temperature control mode.
Examples of modulation waveforms include but are not limited to a pulse train of square waves, sinusoidal, or any other waveform types. In the case of square wave modulation, the modulated RF energy can be characterized in terms of a pulse width (the time of an individual pulse of RF energy) and a duty cycle (the percent of time the RF output is applied). A suitable duty cycle can be up to 100% which is essentially applying RF energy without modulation. Duty cycles up to 80% or up to 50% may also be suitable for limiting collateral damage or to localize the affect of the applied energy.
Feedback Algorithm
As indicated above, the present invention includes controllers having various algorithms. The algorithms may be either analog and digital based. A preferred embodiment is a three parameter controller, or Proportional-Integral-Derivative (PID) controller which employs the following algorithm: Pi+1=Pi+G(αei+βei−1+γei−2) where Pi+1 is a new power set point, Pi is a previous power set point, α, β and γ are preset values, G is a variable gain factor and ei, ei−1, ei−2 correspond to error at the present time step, error one step previous and error two steps previous where the error is the difference between the preset temperature and a measured temperature.
We have found that by using a variable gain factor (G) to adaptively control RF energy delivery, the system of the present invention can treat a wide range of tissue types including lung tissue bronchus, bronchioles and other airway passages. The variable gain factor scales the coefficients (alpha, beta, and gamma; each a function of the three PID parameters) based on, for example, the temperature response to energy input during the initial temperature ramp up.
Exemplary PID parameters are presented herein, expressed in alpha-beta-gamma space, for an energy delivering device and controller of the present invention. These settings and timings are based on testing in various animal lung tissues using an energy delivering apparatus as described above. First, the gain factor preferably varies and is reset 0.1 to 2 and more preferably at 0.5 seconds after energy delivery has begun. Preferably, the gain factor is reset as follows: G is reset to 0.9 to 1.0 and preferably 0.9 if a temperature rise in ° C. per Joule is less than or equal to 2.5; G is reset to 0.4 to 0.5 and preferably 0.5 if a temperature rise in ° C. per Joule is between 2.5 to 5.0; G is reset to 02 to 03 and preferably 0.2 if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and G is reset to 0.1 to 0.2 and preferably 0.1 if a temperature rise in ° C. per Joule is greater than 7.5. We have also found that a suitable value for α is from 1 to 2; for β is from −1 to −2; and for γ is from −0.5 to 0.5. More preferably α, β, γ are 1.6, −1.6, and 0.0 respectively.
It is also possible to change the relative weights of alpha, beta, and gamma depending upon monitored temperature response working in either PID or Alpha-Beta-Gamma coordinate space beyond just scaling the alpha-beta-gamma coefficients with a variable gain factor. This can be done by individually adjusting any or all of alpha, beta, or gamma.
In another variation of the present invention, the PID algorithm is Pi+1=Pi+(G1ei+G2ei−1+G3ei−2) and G1, G2 and G3 are each variable gain factors. The invention includes configuring the controller such that G1, G2 and G3 are reset to 0.90 to 2.00, −0.90 to −2.00 and 0.50 to −0.50 respectively if a temperature rise in ° C. per Joule is less than or equal to 2.5; to 0.40 to 1.00, −0.40 to −1.00 and 0.25 to −025 respectively if a temperature rise in. ° C. per Joule is between 2.5 to 5.0; to 0.20 to 0.60, −0.20 to −0.60 and 0.15 to −0.15 respectively if a temperature rise in ° C. per Joule is equal to 5.0 to 7.5; and to 0.10 to 0.40, −0.10 to −0.40 and 0.10 to −0.10 respectively if a temperature rise in ° C. per Joule is greater than 7.5. Each of the variable gain factors may be equal to a product of at least one preset value and at least one variable value.
It is also possible to employ an algorithm that continuously adapts to signals rather than at discrete sample steps, intervals or periods. The algorithm takes into account several variables upon which observed temperature response depends including, for example: initial temperature, time history of energy delivery, and the amount of energy required to maintain set point temperature. An exemplary analog PID algorithm is: u=KPe+KI∫edt+KD(de/dt) where u is a signal to be adjusted such as, for example, a current, a voltage difference, or an output power which results in energy delivery from the electrode to the airway wall. KP, KI and KD are preset or variable values which are multiplied with the proper error term where e(t) is the difference between a preset variable and a measured process variable such as temperature at time (t). The above equation is suitable for continuous and/or analog type controllers.
Power Shut Down Safety Algorithms
In addition to the control modes specified above, the power supply may include control algorithms to limit excessive thermal damage to the airway tissue. Damage may be limited by terminating or shutting down the energy being delivered to the target medium. The algorithms can be based on the expectation that the sensed temperature of the tissue will respond upon the application of energy. The temperature response, for example, may be a change in temperature in a specified time or the rate of change of temperature. The expected temperature response can be predicted as a function of the initially sensed temperature, the temperature data for a specified power level as a function of time, or any other variables found to affect tissue properties. The expected temperature response may thus be used as a parameter in a power supply safety algorithm. For example, if the measured temperature response is not within a predefined range of the expected temperature response, the power supply will automatically shut down.
Other control algorithms may also be employed. For example, an algorithm may be employed to shut down energy delivery if the sensed temperature does not rise by a certain number of degrees in a pre-specified amount of time after energy delivery begins. Preferably, if the sensed temperature does not increase more than about 10° C. in about 3 seconds, the power supply is shut off. More preferably, if the sensed temperature does not increase more than about 10° C. in about 1 second, the power supply is shut off.
Another way to stop energy delivery includes shutting down a power supply if the temperature ramp is not within a predefined range at any time during energy delivery. For example, if the measured rate of temperature change does not reach a predefined value, the power supply will stop delivery of the RF energy. The predefined values are predetermined and based on empirical data. Generally, the predefined values are based on the duration of time RF energy is delivered and the power-level applied. A suitable predefined rate of temperature change to stop energy delivery is from 8° C./second to 15° C./second in the first 5 seconds (preferably in the first 2 seconds) of commencing energy delivery.
Other algorithms include shutting down a power supply if a maximum temperature setting is exceeded or shutting down a power supply if the sensed temperature suddenly changes, such a change includes either a drop or rise, this change may indicate failure of the temperature sensing element. For example, the generator or power supply may be programmed to shut off if the sensed temperature drops more than about 10° C. in about 0.1 to 1 seconds and more preferably in about 0.2 seconds.
In another configuration, the power is terminated when the measured temperature exceeds a pre-selected temperature or exceeds the set point temperature by a pre-selected amount. For example, when the set point is exceeded by 5 to 20° C., more preferably 15° C. the power will terminate.
In another configuration, power is terminated when the measured temperature (averaged over a time window) exceeds a pre-selected temperature. For example, power may be terminated when the measured temperature (averaged over 1 to 5 seconds and preferably averaged over 2 seconds) exceeds the preset temperature by a predetermined amount. The predetermined amount is generally from 1 to 10° C. and preferably about 5° C. Suitable preset temperatures are from 60 to 80° C. and most preferably about 65° C. Accordingly, in one exemplary configuration, the power is stopped when the measured temperature (averaged over 2 seconds) exceeds 70° C.
In another configuration, the power is terminated when the amount of energy delivered exceeds a maximum amount. A suitable maximum amount is 120 Joules for an energy delivery apparatus delivering energy to the airways of lungs.
In another configuration, the power is shut down depending on an impedance measurement. The impedance is monitored across a treated area of tissue within the lung. Impedance may also be monitored at more than one site within the lungs. The measuring of impedance may be but is not necessarily performed by the same electrodes used to deliver the energy treatment to the tissue. The impedance may be measured as is known in the art and as taught in U.S. application Ser. No. 09/436,455 which is incorporated by reference in its entirety. Accordingly, in one variation of the present invention, the power is adjusted or shut off when a measured impedance drops below a preset impedance value. When using the energy delivering device of the present invention to treat airways, a suitable range for the preset impedance value is from 40 to 60 ohms and preferably about 50 ohms.
In another variation, the energy delivery apparatus is configured to deliver an amount of power up to a maximum power. The maximum power can be from 10 to 40 watts and preferably from 15 to 20 watts.
In yet another configuration, the power supply is configured to shut down if the power delivered exceeds a maximum power and the measured temperature drops by a critical temperature difference within a sampling period of time. A suitable maximum power is from 15 to 20 Watts and preferably about 17 watts. The sampling period of time generally ranges from 0.1 to 1.0 seconds and preferably is about 0.5 seconds. A suitable range for the critical temperature difference is about 2° C.
It is to be understood that any of the above algorithms and shut-down configurations may be combined in a single controller. However, algorithms having mutually exclusive functions may not be combined.
While the power supply or generator preferably includes or employs a microprocessor, the invention is not so limited. Other means known in the art may be employed. For example, the generator may be hardwired to run one or more of the above discussed algorithms.
The controller is preferably programmable and configured to receive and manipulate other signals than the examples provided above. For example, other useful sensors may provide input signals to the processor to be used in determining the power output for the next step. The treatment of an airway may also involve placing a visualization system such as an endoscope or bronchoscope into the airways. The treatment device is then inserted through or next to the bronchoscope or endoscope while visualizing the airways. Alternatively, the visualization system may be built directly into the treatment device using fiber optic imaging and lenses or a CCD and lens arranged at the distal portion of the treatment device. The treatment device may also be positioned using radiographic visualization such as fluoroscopy or other external visualization means.
A system to treat airways in accordance with the present invention was built and tested in vivo on two canines. The system included an energy delivering apparatus having a distal basket. The basket included electrode legs and a temperature sensor mounted to one of the legs. The system also included a generator programmed to measure the temperature change per energy unit during the first half-second of treatment. A PID gain factor was adjusted depending on the measured tissue response. That is, the gain factor was adjusted based on the temperature change per joule output during the first half second. In general, this corresponds to a higher gain for less responsive tissue and lower gain for more responsive tissue.
After treating the test subjects with a general anesthetic, RF energy was delivered to target regions using an energy delivery device and generator as described above. In particular, energy activations were performed on all available intraparenchyma 1 airways three millimeters or larger in diameter in both lungs. Three hundred sixty-three activations using a 65° C. temperature setting were performed in the two animals (i.e., 180 activations per animal). Additionally, in twenty of the activations in each animal, the energy delivery device was deliberately deployed improperly to provide a “Stress” condition.
In each activation, the measured temperature reached and stabilized at 65° C. or, in the case of the twenty activations under “stress” conditions, the power properly shut off. Thus, the present invention can successfully treat lung tissue with a variable gain setting and various safety algorithms to safely maintain a preset temperature at the electrode or lung tissue surface. This temperature control is particularly advantageous when treating the airways of lungs to reduce asthma symptoms.
This invention has been described and specific embodiments or examples of the invention have been portrayed to convey a proper understanding of the invention. The use of such examples is not intended to limit the invention in any way. Additionally, to the extent that there are variations of the invention which are within the spirit of the disclosure and are equivalent to features found in the claims, it is the intent that the claims cover those variations as well. All equivalents are considered to be within the scope of the claimed invention, even those which may not have been set forth herein merely for the sake of brevity. Also, the various aspects of the invention described herein may be modified and/or used in combination with such other aspects also described to be part of the invention either explicitly or inherently to form other advantageous variations considered to be part of the invention covered by the claims which follow.
The invention described herein expressly incorporates the following co-pending applications by reference in their entirety: U.S. application Ser. No. 09/095,323; U.S. application Ser. No. 09/095,323; U.S. application Ser. No. 09/349,715; U.S. application Ser. No. 09/296,040; U.S. application Ser. No. 09/436,455; and U.S. application Ser. No. 09/535,856.
This application is a continuation of U.S. patent application Ser. No. 11/458,074, filed Jul. 17, 2006, now U.S. Pat. No. 7,854,734, which is a continuation of U.S. patent application Ser. No. 10/414,411, filed Apr. 14, 2003, now U.S. Pat. No. 7,104,987, which is a continuation of International Patent Application No. PCT/US01/032321, filed Oct. 17, 2001. U.S. patent application Ser. No. 10/414,411, filed Apr. 14, 2003, now U.S. Pat. No. 7,104,987, is also a continuation-in-part of International Application No. PCT/US00/028745, filed Oct. 17, 2000, the contents of which are hereby incorporated by reference in their entirety
Number | Name | Date | Kind |
---|---|---|---|
612724 | Hamilton | Oct 1898 | A |
1155169 | Starkweather | Sep 1915 | A |
1207479 | Bisgaard | Dec 1916 | A |
1216183 | Swingle | Feb 1917 | A |
2072346 | Smith | Mar 1937 | A |
3320957 | Sokolik | May 1967 | A |
3568659 | Karnegis | Mar 1971 | A |
3667476 | Muller | Jun 1972 | A |
3692029 | Adair | Sep 1972 | A |
3995617 | Watkins et al. | Dec 1976 | A |
4095602 | Leveen | Jun 1978 | A |
4116589 | Rishton | Sep 1978 | A |
4129129 | Amrine | Dec 1978 | A |
4154246 | Leveen | May 1979 | A |
4461283 | Doi | Jul 1984 | A |
4502490 | Evans et al. | Mar 1985 | A |
4503855 | Maslanka | Mar 1985 | A |
4512762 | Spears | Apr 1985 | A |
4522212 | Gelinas et al. | Jun 1985 | A |
4557272 | Carr | Dec 1985 | A |
4565200 | Cosman | Jan 1986 | A |
4567882 | Heller | Feb 1986 | A |
4584998 | McGrail | Apr 1986 | A |
4612934 | Borkan | Sep 1986 | A |
4621642 | Chen | Nov 1986 | A |
4621882 | Krumme | Nov 1986 | A |
4625712 | Wampler | Dec 1986 | A |
4643186 | Rosen et al. | Feb 1987 | A |
4646737 | Hussein et al. | Mar 1987 | A |
4674497 | Ogasawara | Jun 1987 | A |
4683890 | Hewson | Aug 1987 | A |
4704121 | Moise | Nov 1987 | A |
4706688 | Don Michael et al. | Nov 1987 | A |
4709698 | Johnston et al. | Dec 1987 | A |
4739759 | Rexroth et al. | Apr 1988 | A |
4754065 | Levenson et al. | Jun 1988 | A |
4754752 | Ginsburg et al. | Jul 1988 | A |
4765959 | Fukasawa | Aug 1988 | A |
4772112 | Zider et al. | Sep 1988 | A |
4773899 | Spears | Sep 1988 | A |
4779614 | Moise | Oct 1988 | A |
4784135 | Blum et al. | Nov 1988 | A |
4790305 | Zoltan et al. | Dec 1988 | A |
4799479 | Spears | Jan 1989 | A |
4802492 | Grunstein | Feb 1989 | A |
4817586 | Wampler | Apr 1989 | A |
4825871 | Cansell | May 1989 | A |
4827935 | Geddes et al. | May 1989 | A |
4846152 | Wampler et al. | Jul 1989 | A |
4862886 | Clarke et al. | Sep 1989 | A |
4895557 | Moise et al. | Jan 1990 | A |
4906229 | Wampler | Mar 1990 | A |
4907589 | Cosman | Mar 1990 | A |
4908012 | Moise et al. | Mar 1990 | A |
4920978 | Colvin | May 1990 | A |
4944722 | Carriker et al. | Jul 1990 | A |
4955377 | Lennox et al. | Sep 1990 | A |
4967765 | Turner et al. | Nov 1990 | A |
4969865 | Hwang et al. | Nov 1990 | A |
4976709 | Sand | Dec 1990 | A |
4985014 | Orejola | Jan 1991 | A |
4991603 | Cohen et al. | Feb 1991 | A |
5009636 | Wortley et al. | Apr 1991 | A |
5009936 | Yamanaka et al. | Apr 1991 | A |
5010892 | Colvin et al. | Apr 1991 | A |
5019075 | Spears et al. | May 1991 | A |
5027829 | Larsen | Jul 1991 | A |
5030645 | Kollonitsch | Jul 1991 | A |
5036848 | Hewson | Aug 1991 | A |
5053033 | Clarke | Oct 1991 | A |
5056519 | Vince | Oct 1991 | A |
5074860 | Gregory et al. | Dec 1991 | A |
5078716 | Doll | Jan 1992 | A |
5084044 | Quint | Jan 1992 | A |
5096916 | Skupin | Mar 1992 | A |
5100388 | Behl et al. | Mar 1992 | A |
5100423 | Fearnot | Mar 1992 | A |
5103804 | Abele et al. | Apr 1992 | A |
5105826 | Smits et al. | Apr 1992 | A |
5106360 | Ishiwara et al. | Apr 1992 | A |
5107830 | Younes | Apr 1992 | A |
5114423 | Kasprzyk et al. | May 1992 | A |
5116864 | March et al. | May 1992 | A |
5117828 | Metzger et al. | Jun 1992 | A |
5135517 | McCoy | Aug 1992 | A |
5152286 | Sitko et al. | Oct 1992 | A |
5165420 | Strickland | Nov 1992 | A |
5167223 | Koros et al. | Dec 1992 | A |
5170803 | Hewson et al. | Dec 1992 | A |
5174288 | Bardy et al. | Dec 1992 | A |
5188602 | Nichols | Feb 1993 | A |
5191883 | Lennox et al. | Mar 1993 | A |
5213576 | Abiuso et al. | May 1993 | A |
5215103 | Desai | Jun 1993 | A |
5231996 | Bardy et al. | Aug 1993 | A |
5232444 | Just et al. | Aug 1993 | A |
5234456 | Silvestrini | Aug 1993 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5255678 | Deslauriers et al. | Oct 1993 | A |
5255679 | Imran | Oct 1993 | A |
5265604 | Vince | Nov 1993 | A |
5269758 | Taheri | Dec 1993 | A |
5281218 | Imran | Jan 1994 | A |
5292331 | Boneau | Mar 1994 | A |
5293869 | Edwards et al. | Mar 1994 | A |
5309910 | Edwards et al. | May 1994 | A |
5313943 | Houser et al. | May 1994 | A |
5324284 | Imran | Jun 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5343936 | Beatenbough et al. | Sep 1994 | A |
5345936 | Pomeranz et al. | Sep 1994 | A |
5366443 | Eggers et al. | Nov 1994 | A |
5368591 | Lennox et al. | Nov 1994 | A |
5370644 | Langberg | Dec 1994 | A |
5370679 | Atlee, III | Dec 1994 | A |
5374287 | Rubin | Dec 1994 | A |
5383917 | Desai et al. | Jan 1995 | A |
5393207 | Maher et al. | Feb 1995 | A |
5394880 | Atlee, III | Mar 1995 | A |
5396887 | Imran | Mar 1995 | A |
5400778 | Jonson et al. | Mar 1995 | A |
5400783 | Pomeranz et al. | Mar 1995 | A |
5411025 | Webster, Jr. | May 1995 | A |
5415166 | Imran | May 1995 | A |
5415656 | Tihon et al. | May 1995 | A |
5417687 | Nardella et al. | May 1995 | A |
5422362 | Vincent et al. | Jun 1995 | A |
5423744 | Gencheff et al. | Jun 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5425023 | Haraguchi et al. | Jun 1995 | A |
5425703 | Feiring | Jun 1995 | A |
5425811 | Mashita | Jun 1995 | A |
5431696 | Atlee, III | Jul 1995 | A |
5433730 | Alt | Jul 1995 | A |
5437665 | Munro | Aug 1995 | A |
5443470 | Stern et al. | Aug 1995 | A |
5454782 | Perkins | Oct 1995 | A |
5456667 | Ham et al. | Oct 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5465717 | Imran et al. | Nov 1995 | A |
5471982 | Edwards et al. | Dec 1995 | A |
5474530 | Passafaro et al. | Dec 1995 | A |
5478309 | Sweezer et al. | Dec 1995 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5496271 | Burton et al. | Mar 1996 | A |
5496311 | Abele et al. | Mar 1996 | A |
5496312 | Klicek | Mar 1996 | A |
5500011 | Desai | Mar 1996 | A |
5505728 | Ellman et al. | Apr 1996 | A |
5505730 | Edwards | Apr 1996 | A |
5507791 | Sit'ko | Apr 1996 | A |
5509419 | Edwards et al. | Apr 1996 | A |
5522862 | Testerman et al. | Jun 1996 | A |
5531779 | Dahl et al. | Jul 1996 | A |
5540681 | Strul et al. | Jul 1996 | A |
5545161 | Imran | Aug 1996 | A |
5545193 | Fleischman et al. | Aug 1996 | A |
5547469 | Rowland et al. | Aug 1996 | A |
5549559 | Eshel | Aug 1996 | A |
5549655 | Erickson | Aug 1996 | A |
5549661 | Kordis et al. | Aug 1996 | A |
RE35330 | Malone et al. | Sep 1996 | E |
5558073 | Pomeranz et al. | Sep 1996 | A |
5562608 | Sekins et al. | Oct 1996 | A |
5571074 | Buckman, Jr. et al. | Nov 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5574059 | Regunathan et al. | Nov 1996 | A |
5578072 | Barone et al. | Nov 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5588432 | Crowley | Dec 1996 | A |
5588812 | Taylor et al. | Dec 1996 | A |
5595183 | Swanson et al. | Jan 1997 | A |
5598848 | Swanson et al. | Feb 1997 | A |
5599345 | Edwards et al. | Feb 1997 | A |
5601088 | Swanson et al. | Feb 1997 | A |
5605157 | Panescu et al. | Feb 1997 | A |
5607419 | Amplatz et al. | Mar 1997 | A |
5607462 | Imran | Mar 1997 | A |
5620438 | Amplatz et al. | Apr 1997 | A |
5623940 | Daikuzono | Apr 1997 | A |
5624439 | Edwards et al. | Apr 1997 | A |
5626618 | Ward et al. | May 1997 | A |
5630425 | Panescu et al. | May 1997 | A |
5630794 | Lax et al. | May 1997 | A |
5634471 | Fairfax et al. | Jun 1997 | A |
5641326 | Adams | Jun 1997 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5660175 | Dayal | Aug 1997 | A |
5678535 | Dimarco | Oct 1997 | A |
5680860 | Imran | Oct 1997 | A |
5681280 | Rusk et al. | Oct 1997 | A |
5681308 | Edwards et al. | Oct 1997 | A |
5687723 | Avitall | Nov 1997 | A |
5688267 | Panescu et al. | Nov 1997 | A |
5693078 | Desai et al. | Dec 1997 | A |
5694934 | Edelman | Dec 1997 | A |
5695471 | Wampler | Dec 1997 | A |
5699799 | Xu et al. | Dec 1997 | A |
5702386 | Stern et al. | Dec 1997 | A |
5707218 | Maher et al. | Jan 1998 | A |
5707336 | Rubin | Jan 1998 | A |
5707352 | Sekins et al. | Jan 1998 | A |
5722401 | Pietroski et al. | Mar 1998 | A |
5722403 | McGee et al. | Mar 1998 | A |
5722416 | Swanson et al. | Mar 1998 | A |
5725525 | Kordis | Mar 1998 | A |
5727569 | Benetti et al. | Mar 1998 | A |
5728094 | Edwards | Mar 1998 | A |
5730128 | Pomeranz et al. | Mar 1998 | A |
5730704 | Avitall | Mar 1998 | A |
5730726 | Klingenstein | Mar 1998 | A |
5730741 | Horzewski et al. | Mar 1998 | A |
5735846 | Panescu et al. | Apr 1998 | A |
5740808 | Panescu et al. | Apr 1998 | A |
5741248 | Stern et al. | Apr 1998 | A |
5752518 | McGee et al. | May 1998 | A |
5755714 | Murphy-Chutorian | May 1998 | A |
5755715 | Stern et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5759158 | Swanson | Jun 1998 | A |
5765568 | Sweezer, Jr. et al. | Jun 1998 | A |
5769846 | Edwards et al. | Jun 1998 | A |
5769847 | Panescu et al. | Jun 1998 | A |
5772590 | Webster, Jr. | Jun 1998 | A |
5779669 | Haissaguerre et al. | Jul 1998 | A |
5779698 | Clayman et al. | Jul 1998 | A |
5782239 | Webster, Jr. | Jul 1998 | A |
5782797 | Schweich, Jr. et al. | Jul 1998 | A |
5782827 | Gough et al. | Jul 1998 | A |
5782848 | Lennox | Jul 1998 | A |
5782899 | Imran | Jul 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5795303 | Swanson et al. | Aug 1998 | A |
5800375 | Sweezer et al. | Sep 1998 | A |
5807306 | Shapland et al. | Sep 1998 | A |
5810757 | Sweezer, Jr. et al. | Sep 1998 | A |
5810807 | Ganz et al. | Sep 1998 | A |
5817028 | Anderson | Oct 1998 | A |
5817073 | Krespi | Oct 1998 | A |
5820554 | Davis et al. | Oct 1998 | A |
5823189 | Kordis | Oct 1998 | A |
5827277 | Edwards | Oct 1998 | A |
5833651 | Donovan et al. | Nov 1998 | A |
5836905 | Lemelson et al. | Nov 1998 | A |
5836947 | Fleischman et al. | Nov 1998 | A |
5837001 | Mackey | Nov 1998 | A |
5843075 | Taylor | Dec 1998 | A |
5843077 | Edwards | Dec 1998 | A |
5846238 | Jackson et al. | Dec 1998 | A |
5848969 | Panescu et al. | Dec 1998 | A |
5848972 | Triedman et al. | Dec 1998 | A |
5849026 | Zhou et al. | Dec 1998 | A |
5855577 | Murphy-Chutorian et al. | Jan 1999 | A |
5860974 | Abele | Jan 1999 | A |
5863291 | Schaer | Jan 1999 | A |
5865791 | Whayne et al. | Feb 1999 | A |
5868740 | Leveen et al. | Feb 1999 | A |
5871443 | Edwards et al. | Feb 1999 | A |
5871523 | Fleischman et al. | Feb 1999 | A |
5873852 | Vigil et al. | Feb 1999 | A |
5873865 | Horzewski et al. | Feb 1999 | A |
5876340 | Tu et al. | Mar 1999 | A |
5876399 | Chia et al. | Mar 1999 | A |
5881727 | Edwards | Mar 1999 | A |
5882346 | Pomeranz et al. | Mar 1999 | A |
5891135 | Jackson et al. | Apr 1999 | A |
5891136 | McGee et al. | Apr 1999 | A |
5891138 | Tu et al. | Apr 1999 | A |
5893847 | Kordis | Apr 1999 | A |
5897554 | Chia et al. | Apr 1999 | A |
5899882 | Waksman et al. | May 1999 | A |
5904651 | Swanson et al. | May 1999 | A |
5904711 | Flom et al. | May 1999 | A |
5906636 | Casscells, III et al. | May 1999 | A |
5908445 | Whayne et al. | Jun 1999 | A |
5908446 | Imran | Jun 1999 | A |
5908839 | Levitt et al. | Jun 1999 | A |
5911218 | Dimarco | Jun 1999 | A |
5916235 | Guglielmi | Jun 1999 | A |
5919147 | Jain | Jul 1999 | A |
5919172 | Golba, Jr. | Jul 1999 | A |
5924424 | Stevens et al. | Jul 1999 | A |
5928228 | Kordis et al. | Jul 1999 | A |
5931835 | Mackey | Aug 1999 | A |
5935079 | Swanson et al. | Aug 1999 | A |
5941869 | Patterson et al. | Aug 1999 | A |
5951494 | Wang et al. | Sep 1999 | A |
5951546 | Lorentzen | Sep 1999 | A |
5954661 | Greenspon et al. | Sep 1999 | A |
5954662 | Swanson et al. | Sep 1999 | A |
5954717 | Behl et al. | Sep 1999 | A |
5957920 | Baker | Sep 1999 | A |
5957961 | Maguire et al. | Sep 1999 | A |
5964753 | Edwards | Oct 1999 | A |
5964796 | Imran | Oct 1999 | A |
5971983 | Lesh | Oct 1999 | A |
5972026 | Laufer et al. | Oct 1999 | A |
5976175 | Hirano et al. | Nov 1999 | A |
5976709 | Kageyama et al. | Nov 1999 | A |
5979456 | Magovern | Nov 1999 | A |
5980563 | Tu et al. | Nov 1999 | A |
5984917 | Fleischman et al. | Nov 1999 | A |
5984971 | Faccioli et al. | Nov 1999 | A |
5991650 | Swanson et al. | Nov 1999 | A |
5992419 | Sterzer et al. | Nov 1999 | A |
5993462 | Pomeranz et al. | Nov 1999 | A |
5997534 | Tu et al. | Dec 1999 | A |
5999855 | Dimarco | Dec 1999 | A |
6001054 | Regulla et al. | Dec 1999 | A |
6003517 | Sheffield et al. | Dec 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6006755 | Edwards | Dec 1999 | A |
6008211 | Robinson et al. | Dec 1999 | A |
6009877 | Edwards | Jan 2000 | A |
6010500 | Sherman et al. | Jan 2000 | A |
6014579 | Pomeranz et al. | Jan 2000 | A |
6016437 | Tu et al. | Jan 2000 | A |
6023638 | Swanson | Feb 2000 | A |
6024740 | Lesh et al. | Feb 2000 | A |
6029091 | De La Rama et al. | Feb 2000 | A |
6033397 | Laufer et al. | Mar 2000 | A |
6036687 | Laufer et al. | Mar 2000 | A |
6036689 | Tu et al. | Mar 2000 | A |
6039731 | Taylor et al. | Mar 2000 | A |
6045549 | Smethers et al. | Apr 2000 | A |
6045550 | Simpson et al. | Apr 2000 | A |
6050992 | Nichols | Apr 2000 | A |
6053172 | Hovda et al. | Apr 2000 | A |
6053909 | Shadduck | Apr 2000 | A |
6056744 | Edwards | May 2000 | A |
6056769 | Epstein et al. | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6071280 | Edwards et al. | Jun 2000 | A |
6071281 | Burnside et al. | Jun 2000 | A |
6071282 | Fleischman | Jun 2000 | A |
6083255 | Laufer et al. | Jul 2000 | A |
6090104 | Webster, Jr. | Jul 2000 | A |
6092528 | Edwards | Jul 2000 | A |
6102886 | Lundquist et al. | Aug 2000 | A |
6106524 | Eggers et al. | Aug 2000 | A |
6123702 | Swanson et al. | Sep 2000 | A |
6123703 | Tu et al. | Sep 2000 | A |
6139527 | Laufer et al. | Oct 2000 | A |
6139571 | Fuller et al. | Oct 2000 | A |
6142993 | Whayne et al. | Nov 2000 | A |
6143013 | Samson et al. | Nov 2000 | A |
6149647 | Tu et al. | Nov 2000 | A |
6152143 | Edwards | Nov 2000 | A |
6152899 | Farley et al. | Nov 2000 | A |
6159194 | Eggers et al. | Dec 2000 | A |
6179833 | Taylor | Jan 2001 | B1 |
6183468 | Swanson et al. | Feb 2001 | B1 |
6198970 | Freed et al. | Mar 2001 | B1 |
6200311 | Danek et al. | Mar 2001 | B1 |
6200332 | Del Giglio | Mar 2001 | B1 |
6200333 | Laufer | Mar 2001 | B1 |
6210367 | Carr | Apr 2001 | B1 |
6212433 | Behl | Apr 2001 | B1 |
6214002 | Fleischman et al. | Apr 2001 | B1 |
6216043 | Swanson et al. | Apr 2001 | B1 |
6216044 | Kordis | Apr 2001 | B1 |
6217576 | Tu et al. | Apr 2001 | B1 |
6235024 | Tu | May 2001 | B1 |
6241727 | Tu et al. | Jun 2001 | B1 |
6245065 | Panescu et al. | Jun 2001 | B1 |
6254598 | Edwards et al. | Jul 2001 | B1 |
6258087 | Edwards et al. | Jul 2001 | B1 |
6264653 | Falwell | Jul 2001 | B1 |
6269813 | Fitzgerald et al. | Aug 2001 | B1 |
6270476 | Santoianni et al. | Aug 2001 | B1 |
6273907 | Laufer | Aug 2001 | B1 |
6283988 | Laufer et al. | Sep 2001 | B1 |
6283989 | Laufer et al. | Sep 2001 | B1 |
6287304 | Eggers et al. | Sep 2001 | B1 |
6296639 | Truckai et al. | Oct 2001 | B1 |
6299633 | Laufer | Oct 2001 | B1 |
6322559 | Daulton et al. | Nov 2001 | B1 |
6322584 | Ingle et al. | Nov 2001 | B2 |
6338727 | Noda et al. | Jan 2002 | B1 |
6338836 | Kuth et al. | Jan 2002 | B1 |
6346104 | Daly et al. | Feb 2002 | B2 |
6355031 | Edwards et al. | Mar 2002 | B1 |
6379352 | Reynolds et al. | Apr 2002 | B1 |
6409723 | Edwards | Jun 2002 | B1 |
6411852 | Danek et al. | Jun 2002 | B1 |
6416511 | Lesh et al. | Jul 2002 | B1 |
6416740 | Unger | Jul 2002 | B1 |
6423105 | Iijima et al. | Jul 2002 | B1 |
6425895 | Swanson et al. | Jul 2002 | B1 |
6440129 | Simpson | Aug 2002 | B1 |
6442435 | King et al. | Aug 2002 | B2 |
6458121 | Rosenstock et al. | Oct 2002 | B1 |
6460545 | Kordis | Oct 2002 | B2 |
6488673 | Laufer et al. | Dec 2002 | B1 |
6488679 | Swanson et al. | Dec 2002 | B1 |
6493589 | Medhkour et al. | Dec 2002 | B1 |
6494880 | Swanson et al. | Dec 2002 | B1 |
6496738 | Carr | Dec 2002 | B2 |
6514246 | Swanson et al. | Feb 2003 | B1 |
6526320 | Mitchell | Feb 2003 | B2 |
6529756 | Phan et al. | Mar 2003 | B1 |
6544226 | Gaiser et al. | Apr 2003 | B1 |
6544262 | Fleischman | Apr 2003 | B2 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6558378 | Sherman et al. | May 2003 | B2 |
6572612 | Stewart et al. | Jun 2003 | B2 |
6575623 | Werneth | Jun 2003 | B2 |
6575969 | Rittman, III et al. | Jun 2003 | B1 |
6582427 | Goble et al. | Jun 2003 | B1 |
6582430 | Hall | Jun 2003 | B2 |
6589235 | Wong et al. | Jul 2003 | B2 |
6610054 | Edwards et al. | Aug 2003 | B1 |
6620159 | Hegde | Sep 2003 | B2 |
6626903 | McGuckin, Jr. et al. | Sep 2003 | B2 |
6634363 | Danek et al. | Oct 2003 | B1 |
6635056 | Kadhiresan et al. | Oct 2003 | B2 |
6638273 | Farley et al. | Oct 2003 | B1 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6645200 | Koblish et al. | Nov 2003 | B1 |
6652548 | Evans et al. | Nov 2003 | B2 |
6669693 | Friedman | Dec 2003 | B2 |
6673068 | Berube | Jan 2004 | B1 |
6692492 | Simpson et al. | Feb 2004 | B2 |
6699243 | West et al. | Mar 2004 | B2 |
6714822 | King et al. | Mar 2004 | B2 |
6723091 | Goble et al. | Apr 2004 | B2 |
6743197 | Edwards | Jun 2004 | B1 |
6749604 | Eggers et al. | Jun 2004 | B1 |
6749606 | Keast et al. | Jun 2004 | B2 |
6767347 | Sharkey et al. | Jul 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6802843 | Truckai et al. | Oct 2004 | B2 |
6805131 | Kordis | Oct 2004 | B2 |
6837888 | Ciarrocca et al. | Jan 2005 | B2 |
6840243 | Deem et al. | Jan 2005 | B2 |
6849073 | Hoey et al. | Feb 2005 | B2 |
6852091 | Edwards et al. | Feb 2005 | B2 |
6852110 | Roy et al. | Feb 2005 | B2 |
6866662 | Fuimaono et al. | Mar 2005 | B2 |
6881213 | Ryan et al. | Apr 2005 | B2 |
6893436 | Woodard et al. | May 2005 | B2 |
6893439 | Fleischman | May 2005 | B2 |
6895267 | Panescu et al. | May 2005 | B2 |
6904303 | Phan et al. | Jun 2005 | B2 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6939346 | Kannenberg et al. | Sep 2005 | B2 |
6954977 | Maguire et al. | Oct 2005 | B2 |
7027869 | Danek et al. | Apr 2006 | B2 |
7043307 | Zelickson et al. | May 2006 | B1 |
7104987 | Biggs et al. | Sep 2006 | B2 |
7104990 | Jenkins et al. | Sep 2006 | B2 |
7118568 | Hassett et al. | Oct 2006 | B2 |
7122033 | Wood | Oct 2006 | B2 |
7131445 | Amoah | Nov 2006 | B2 |
7186251 | Malecki et al. | Mar 2007 | B2 |
7198635 | Danek et al. | Apr 2007 | B2 |
7200445 | Dalbec et al. | Apr 2007 | B1 |
7241295 | Maguire | Jul 2007 | B2 |
7255693 | Johnston et al. | Aug 2007 | B1 |
7264002 | Danek et al. | Sep 2007 | B2 |
7266414 | Cornelius et al. | Sep 2007 | B2 |
7273055 | Danek et al. | Sep 2007 | B2 |
7425212 | Danek et al. | Sep 2008 | B1 |
7542802 | Biggs et al. | Jun 2009 | B2 |
7556624 | Laufer et al. | Jul 2009 | B2 |
7740017 | Danek et al. | Jun 2010 | B2 |
20030050631 | Mody et al. | Mar 2003 | A1 |
20030065371 | Satake | Apr 2003 | A1 |
20030069570 | Witzel et al. | Apr 2003 | A1 |
20030187430 | Vorisek | Oct 2003 | A1 |
20030236455 | Swanson et al. | Dec 2003 | A1 |
20040153056 | Muller et al. | Aug 2004 | A1 |
20040249401 | Rabiner et al. | Dec 2004 | A1 |
20050010270 | Laufer | Jan 2005 | A1 |
20050096644 | Hall et al. | May 2005 | A1 |
20050171396 | Pankratov et al. | Aug 2005 | A1 |
20050193279 | Daners | Sep 2005 | A1 |
20050203503 | Edwards et al. | Sep 2005 | A1 |
20050240176 | Oral et al. | Oct 2005 | A1 |
20050251128 | Amoah | Nov 2005 | A1 |
20060062808 | Laufer et al. | Mar 2006 | A1 |
20060079887 | Buysse et al. | Apr 2006 | A1 |
20060089637 | Werneth et al. | Apr 2006 | A1 |
20060135953 | Kania et al. | Jun 2006 | A1 |
20060137698 | Danek et al. | Jun 2006 | A1 |
20060247617 | Danek et al. | Nov 2006 | A1 |
20060247618 | Kaplan et al. | Nov 2006 | A1 |
20060247619 | Kaplan et al. | Nov 2006 | A1 |
20060247727 | Biggs et al. | Nov 2006 | A1 |
20060247746 | Danek et al. | Nov 2006 | A1 |
20060254600 | Danek et al. | Nov 2006 | A1 |
20060278243 | Danek et al. | Dec 2006 | A1 |
20060278244 | Danek et al. | Dec 2006 | A1 |
20060282071 | Utley et al. | Dec 2006 | A1 |
20070074719 | Danek et al. | Apr 2007 | A1 |
20070083194 | Kunis et al. | Apr 2007 | A1 |
20070083197 | Danek et al. | Apr 2007 | A1 |
20070100390 | Danaek et al. | May 2007 | A1 |
20070102011 | Danek et al. | May 2007 | A1 |
20070106292 | Kaplan et al. | May 2007 | A1 |
20070106296 | Laufer et al. | May 2007 | A1 |
20070106348 | Laufer | May 2007 | A1 |
20070118184 | Danek et al. | May 2007 | A1 |
20070118190 | Danek et al. | May 2007 | A1 |
20070123958 | Laufer | May 2007 | A1 |
20070123961 | Danek et al. | May 2007 | A1 |
20070129720 | Demarais et al. | Jun 2007 | A1 |
20080004596 | Yun et al. | Jan 2008 | A1 |
20080097424 | Wizeman et al. | Apr 2008 | A1 |
20080255642 | Zarins et al. | Oct 2008 | A1 |
20090018538 | Webster et al. | Jan 2009 | A1 |
20090030477 | Jarrard | Jan 2009 | A1 |
20090043301 | Jarrard et al. | Feb 2009 | A1 |
20090069797 | Danek et al. | Mar 2009 | A1 |
20090112203 | Danek et al. | Apr 2009 | A1 |
20090143705 | Danek et al. | Jun 2009 | A1 |
20090143776 | Danek et al. | Jun 2009 | A1 |
20090192505 | Askew et al. | Jul 2009 | A1 |
20090192508 | Laufer et al. | Jul 2009 | A1 |
20090306644 | Mayse et al. | Dec 2009 | A1 |
20100160906 | Jarrard | Jun 2010 | A1 |
20100185190 | Danek et al. | Jul 2010 | A1 |
20100204689 | Danek et al. | Aug 2010 | A1 |
Number | Date | Country |
---|---|---|
19529634 | Feb 1997 | DE |
189329 | Jun 1987 | EP |
280225 | Mar 1989 | EP |
286145 | Oct 1990 | EP |
282225 | Jun 1992 | EP |
908150 | Apr 1999 | EP |
908713 | Apr 1999 | EP |
768091 | Jul 2003 | EP |
1297795 | Aug 2005 | EP |
2659240 | Jul 1997 | FR |
2233293 | Jan 1991 | GB |
2233293 | Feb 1994 | GB |
59167707 | Sep 1984 | JP |
7289557 | Nov 1995 | JP |
9047518 | Feb 1997 | JP |
9243837 | Sep 1997 | JP |
10026709 | Jan 1998 | JP |
2053814 | Feb 1996 | RU |
2091054 | Sep 1997 | RU |
545358 | Feb 1977 | SU |
WO8911311 | Nov 1989 | WO |
WO9502370 | Jan 1995 | WO |
WO9510322 | Apr 1995 | WO |
WO9604860 | Feb 1996 | WO |
WO9610961 | Apr 1996 | WO |
WO9732532 | Sep 1997 | WO |
WO9733715 | Sep 1997 | WO |
WO9737715 | Oct 1997 | WO |
WO9740751 | Nov 1997 | WO |
WO9844854 | Oct 1998 | WO |
WO9852480 | Nov 1998 | WO |
WO9856234 | Dec 1998 | WO |
WO9856324 | Dec 1998 | WO |
WO9858681 | Dec 1998 | WO |
WO9903413 | Jan 1999 | WO |
WO9913779 | Mar 1999 | WO |
WO9932040 | Jul 1999 | WO |
WO9934741 | Jul 1999 | WO |
WO9944506 | Sep 1999 | WO |
WO9945855 | Sep 1999 | WO |
WO9964109 | Dec 1999 | WO |
WO0051510 | Sep 2000 | WO |
WO0062699 | Oct 2000 | WO |
WO0103642 | Jan 2001 | WO |
WO0232333 | Apr 2002 | WO |
WO0232334 | Apr 2002 | WO |
WO2009082433 | Jul 2009 | WO |
WO2009137819 | Nov 2009 | WO |
Entry |
---|
An S. S., et al., “Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma,” European Respiratory Journal, 2007, 29 (5), 834-860. |
Bel, et al., ““Hot stuff”: bronchial thermoplasty for asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173, 941-943. |
Brown R. H., et al., “Effect of bronchial thermoplasty on airway distensibility,” European Respiratory Journal, 2005, 26 (2), 277-282. |
Brown R. H., et al., “In vivo evaluation of the effectiveness of bronchial thermoplasty with computed tomography,” Journal of Applied Physiology, 2005, 98, 1603-1606. |
Chhajed P., et al., “Will there be a role for bronchoscopic radiofrequency ablation?,” J Bronchol, 2005, 12 (3), 184-186. |
Cox G., et al., “Asthma Control during the Year after Bronchial Thermoplasty,” The New England journal of medicine, 2007, 356 (13), 1327-1337. |
Cox G., et al., “Bronchial Thermoplasty for Asthma,” American Journal of Respiratory and Critical Care Medicine, 2006, 173, 965-969. |
Cox G., et al., “Bronchial Thermoplasty: Long-Term Follow-Up and Patient Satisfaction,” Chest, 2004, 126 (4), 822s. |
Cox G., et al., “Bronchial Thermoplasty: One-Year Update, American Thoracic Society Annual Meeting,” Am J Respir Crit Care Med, 2004, 169, A313. |
Cox G., et al., “Clinical Experience With Bronchial Thermoplasty for the Treatment of Asthma,” Chest, 2003, 124, 106S. |
Cox G., et al., “Development of a Novel Bronchoscopic Therapy for Asthma,” Journal of Allergy and Clinical Immunology, 2003, 113 (2), S33. |
Cox G., et al., “Early Clinical Experience with Bronchial Thermoplasty for the Treatment of Asthma, American Thoracic Society Annual Meeting,” 2002, 1068. |
Cox G., et al., “Impact of bronchial thermoplasty on asthma status: interim results from the AIR trial.European Respiratory Society Annual Meeting. Munich, Germany,” 2006, 1 page. |
Cox G., et al., “Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations,” European Respiratory Journal, 2004, 24, 659-663. |
Danek C. J., et al., “Asthma Intervention Research (AIR) Trial Evaluating Bronchial Thermoplasty™: Early Results, American Thoracic Society Annual Meeting,” 2002, 1 page. |
Danek C. J., et al., “Bronchial thermoplasty reduces canine airway responsiveness to local methacholine challenge, American Thoracic Society Annual Meeting,” 2002, 1 page. |
Danek C. J., et al., “Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs,” J Appl Physiol, 2004, 97, 1946-1953. |
Dierkesmann, et al., “Indication and Results of Endobronchial Laser Therapy,” Lung, 1990, 168, 1095-1102. |
Erle C. H., et al., “Botulinum toxin: a novel therapeutic option for bronchial asthma?,” Medical Hypotheses, 2006, 66, 915-919. |
Hogg J. C., “The Pathology of Asthma,” APMIS, 1997, 105 (10), 735-745. |
Ivanyuta O. M., et al., “Effect of Low-Power Laser Irradiation of Bronchial Mucosa on the State of Systemic and Local Immunity in Patients with Chronic Bronchitis,” Problemy Tuberkuleza, 1991, 6, 26-29. |
James, et al., “The Mechanics of Airway Narrowing in Asthma,” Am. Rev. Respir. Dis., 1989, 139, 242-246. |
Johnson S. R., et al., “Synthetic Functions of Airway Smooth Muscle in Asthma,” Trends Pharmacol. Sci., 1997, 18 (8), 288-292. |
Julian Solway M. D., et al., “Airway Smooth Muscle as a Target for Asthma Therapy,” The New England journal of medicine, 2007, 356 (13), 1367-1369. |
Kitamura S., “Color Atlas of Clinical Application of Fiberoptic Bronchoscopy,” 1990, Year Book Medical Publishers, 17. |
Laviolette, et al., “Asthma Intervention Research (Air) Trial: Early Safety Assessment of Bronchial Thermoplasty,” Am J Respir Crit Care Med, 2004, 169, A314. |
Leff, et al., “Bronchial Thermoplasty Alters Airway Smooth Muscle and Reduces Responsiveness in Dogs: A Possible Procedure for the Treatment of Asthma, American Thoracic Society Annual Meeting,” 2002, 1 page. |
Lombard, et al., “Histologic Effects of Bronchial Thermoplasty of Canine and Human Airways, American Thoracic Society Annual Meeting,” 2002, 1 page. |
Macklem P. T., “Mechanical Factors Determining Maximum Bronchoconstriction,” European Respiratory Journal, 1989, 6, 516s-519s. |
Mayse M. L., et al., “Clinical Pearls for Bronchial Thermoplasty,” J Bronchol, 2007, 14 (2), 115-123. |
Miller J. D., et al., “A Prospective Feasibility Study of Bronchial Thermoplasty in the Human Airway,” 2005, 127, 1999-2006. |
Miller J. D., et al., “Bronchial Thermoplasty is Well Tolerated by Non-Asthmatic Patients Requiring Lobectomy, American Thoracic Society Annual Meeting,” 2002, 1 page. |
Netter F. H., “Respiratory System: A Compilation of Paintings Depicting Anatomy and Embryology, Physiology, Pathology, Pathophysiology, and Clinical Features and Treatment of Diseases,In the CIBA Collection of Medical Illustrations M.B. Divertie, ed., Summit: New Jerse,” 1979, 7, 119-135. |
Notice of final Rejection, Japanese Patent Application No. 2000-553172, dated Sep. 2, 2008, 5 pages. |
PCT International search report for application No. PCT/US00/05412 mailed on Jun. 20, 2000, 2 pages. |
PCT International search report for application No. PCT/US00/18197 mailed on Oct. 3, 2000, 1 page. |
PCT International search report for application No. PCT/US00/28745 mailed on Mar. 28, 2001, 6 pages. |
PCT International search report for application No. PCT/US01/32321 mailed on Jan. 18, 2002, 2 pages. |
PCT International search report for application No. PCT/US98/03759 mailed on Jul. 30, 1998, 1 page. |
PCT International search report for application No. PCT/US98/26227 mailed on Mar. 25, 1999, 1 page. |
PCT International search report for application No. PCT/US99/00232 mailed on Mar. 4, 1999, 1 page. |
PCT International search report for application No. PCT/US99/12986 mailed on Sep. 29, 1999, 1 page. |
Provotorov, et al., “The Clinical Efficacy of Treating Patients with Nonspecific Lung Disease by Using Low-energy Laser Irradiation and Intrapulmonary Drug Administration, ISSN: 0040-3660,” Terapevticheskii Arkhiv (USSR), 1991, 62 (12), 18-23. |
Rubin, et al., “Bronchial thermoplasty improves asthma status of moderate to severe perisstent asthmatics over and above current standard-of-care, American College of Chest Physicians,” 2006, 2 pages. |
Shesterina M. V., et al., “Effect of laser therapy on immunity in patients with bronchial asthma and pulmonary tuberculosis,” 1993, 23-26. |
Sterk P. J., et al., “Heterogeneity of airway hyperresponsiveness: time for unconventional, but traditional, studies,” J Appl Physiol, 2004, 96, 2017-2018. |
Toma, et al., “Brave new world for interventional bronchoscopy,” Thorax, 2005, 60, 180-181. |
Trow T., “Clinical Year in Review I Diagnostic Imaging, Asthma, Lung Transplantation, and Interventional Pulmonology,” Proceedings of the American Thoracic Society, 2006, 3, 553-556. |
Vorotnev, et al., “Low energy laser treatment of chronic obstructive bronchitis in a general rehabilitation center,ISSN: 0040-3660,” Terapevticheskii Arkhiv, 1997, 69 (3), 17-19. |
Wayne Mitzner, “Airway Smooth Muscle The appendix of the Lung,” American Journal of Respiratory and Critical Care Medicine, 2004, 169, 787-790. |
Wiggs B. R., et al., “On the Mechanism of Mucosal Folding in Normal and Asthmatic Airways,” J. Appl. Physiol., 1997, 83 (6), 1814-1821. |
Wilson S. R., et al., “Global assessment after bronchial thermoplasty: the patients perspective,” Journal of Outcomes Research, 2006, 10, 37-46. |
Wizeman, et al., “A Computer Model of Thermal Treatment of Airways by Radiofrequency (RF) Energy Delivery, American Thoracic Society Annual Meeting,” 2007, 1 page. |
Number | Date | Country | |
---|---|---|---|
20110172655 A1 | Jul 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11458074 | Jul 2006 | US |
Child | 12944238 | US | |
Parent | 10414411 | Apr 2003 | US |
Child | 11458074 | US | |
Parent | PCT/US01/32321 | Oct 2001 | US |
Child | 10414411 | US |
Number | Date | Country | |
---|---|---|---|
Parent | PCT/US00/28745 | Oct 2000 | US |
Child | PCT/US01/32321 | US |